Product information and disease descriptionPlace of product in therapyDisease description
Natural history, survival, and mortality
21 evidence topics · 19 sources
Five-year relative survival, all uveal melanoma, 1975 to 2016
Five-year and ten-year relative survival, all uveal melanoma
U.S. five-year relative survival by SEER stage, eye melanoma diagnosed 2015 to 2021
Estimated U.S. deaths in 2026, all eye and orbit cancer
| Site, United States, 2026 | Estimated deaths, both sexes | Male | Female |
|---|---|---|---|
| Eye and orbit | “530”View highlighted excerpt for this quote | “280”View highlighted excerpt for this quote | “250”View highlighted excerpt for this quote |
Long-term metastasis-free survival and melanoma-related death
“The KM estimates of MFS were 0.729 (0.719, 0.74), 0.648 (0.633, 0.663), and 0.616 (0.596, 0.636) at 10, 20, and 30 years, respectively. The cumulative probabilities of melanoma metastatic death at 10, 20 and 30 years were 0.241 (0.236, 0.245), 0.289 (0.283, 0.294), and 0.301 (0.295, 0.307).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Death due to melanoma were rare beyond 20 years with normal life expectancy reached at 25 years after primary therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Uveal melanoma-related mortality over 35 years and late metastatic death
“Uveal melanoma-related mortality was 31% (95% confidence interval [CI], 26-37) by 5 years, 45% (95% CI, 40-51) by 15 years, 49% (95% CI, 43-55) by 25 years, and 52% (95% CI, 45-58) by 35 years, according to cumulative incidence analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of patients who died of uveal melanoma, 62%, 90%, 98%, and 100% did so within 5, 15, 25, and 35 years, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Micrometastatic dormancy and late liver metastasis
“Metastatic liver disease is the overwhelming cause of death in uveal melanoma patients, with almost 50% of patients developing liver metastases up to 15 years after diagnosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most of these patients do not present with any evidence of overt metastasis at the time of initial diagnosis although it is assumed that they have undetectable micrometastases.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prognosis after extraocular extension, recurrence, or metastasis
Course after metastasis: liver involvement, survival beyond 5 years, and cure rate
“Almost 50% of patients develop metastatic disease, which usually involves the liver, and is usually fatal within 1 year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Meta-analyses confirm a median overall survival of 10-13 months, and a cure rate that approaches nil, although survival exceeding 5 years is possible, estimated 2% either with first-line treatment or with best supportive care.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Death rate after diagnosis of metastasis, COMS trials
“The death rate following the report of melanoma metastasis was 80% at 1 year (95% confidence interval, 77%-83%) and 92% at 2 years (95% confidence interval, 89%-94%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Long-term survival after diagnosis of metastasis was uncommon; only 8 patients survived 5 or more years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Survival after diagnosis of metastasis with and without treatment
“Overall, the median survival time was poor (3.9 months [IQR, 1.6-10.1]). Patients who received treatment fared better than those who did not receive treatment (median survival after metastasis diagnosis, 6.3 months [IQR, 2.96-14.41] vs 1.7 months [IQR, 0.66-3.5]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pooled overall survival after metastasis, meta-analysis of 78 articles with 2494 participants
“Individual-level data were obtained from 78 articles with 2494 patients. The median OS across all treatment modalities was 1.07 years (range: 0.59–2.50 years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reported OS was unassociated with the decade of publication, but depended on the percentage of first-line treated patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Progression-free and overall survival benchmarks
“The median PFS was 3.3 months (95% CI 2.9-3.6) and 6-month PFS rate was 27% (95% CI 24-30).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median OS was 10.2 months (95% CI 9.5-11.0) and 1 year OS was 43% (95% CI 40-47).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
One-year survival in a cohort with metastatic uveal melanoma
Overall survival with active treatment by working formulation stage
Prognostic factors after metastasis: lactate dehydrogenase, alkaline phosphatase, and liver metastasis size
“Univariable analysis showed male sex, elevated (i.e. > versus ≤ upper limit of normal) lactate dehydrogenase (LDH), elevated alkaline phosphatase (ALP) and diameter of the largest liver metastasis (≥3 cm versus <3 cm) to be substantially associated with shorter PFS.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most substantial prognostic factors for shorter OS by univariable and multivariable analysis were elevated LDH and elevated ALP.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The multivariable Cox analysis showed that slight to moderately elevated LDH (250–500 U/L) and high LDH level (>500 U/L) were a statistically significant factor associated with poor survival (p < 0.001), HR of 1.8 (95% CI 1.07–3.01) and 9.0 (95% CI 5.63–14.35) respectively. Also, the presence of liver metastases was negatively associated with survival, HR 2.09 (95% CI 1.07–4.08, p = 0.03).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Different staging systems predict survival after metastatic disease appears, based on tumour burden, liver function tests, World Health Organization performance status (PS) and metastasis-free interval.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote